Search clinical trials for: Luminal B breast cancer

Total 493360 results

Hubei Cancer Hospital

Not yet recruiting

SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer

Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic Syndrome (PROMETA)

Breast Cancer | Metabolic Syndrome

Italy
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer (CYCLHER)

Advanced Breast Carcinoma

Italy
SOLTI Breast Cancer Research Group

Recruiting

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (SOLTI-2104)

Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Premenopausal Breast Cancer

Spain
Università Vita-Salute San Raffaele
IRCCS San Raffaele; Associazione Italiana per la Ricerca sul Cancro

Not yet recruiting

18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer (FESTA)

Breast Cancer Female | Lobular Breast Carcinoma | Luminal A Breast Cancer | PET/MRI | Axillary Lymphadenopathy
Fudan University

Recruiting

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype (BCTOP-T-M03)

Metastatic Breast Cancer | Triple Negative Breast Cancer | Mutation

China
Fudan University

Recruiting

Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer (BCTOP-L-M01)

Breast Cancer | Advanced Breast Cancer

China
Centro di Riferimento Oncologico - Aviano

Recruiting

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA (MAGNETIC1)

Breast Neoplasms | Breast Diseases | Antineoplastic Agents | Aromatase Inhibitors | Neoplasms, Breast | Hormone Receptor Positive Breast Carcinoma | ESR1 Gene Mutation

Italy
Vastra Gotaland Region
Lund University; Sahlgrenska University Hospital, Sweden

Not yet recruiting

Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC) (I-CONIC)

Breast Cancer | Triple Negative Breast Cancer

Sweden
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Recruiting

Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast Cancer

Breast Cancer | Radiotherapy

Italy
Second Affiliated Hospital, School of Medicine,...
GeneCast Biotechnology Co., Ltd.

Recruiting

Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)

Luminal B/HER2-negative Breast Cancer

China
Salubris Biotherapeutics Inc

Recruiting

Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Melanoma | Clear Cell Renal Cell Carcinoma | Cancer | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Advanced Solid Tumor | Epithelial Ovarian Cancer | Non-small Cell... and other conditions

Belgium, Spain
Moscow Clinical Scientific Center

Recruiting

Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients

Breast Cancer | Pancreas Cancer

Russian Federation
Borstkanker Onderzoek Groep
Novartis Pharma B.V.; BOOG Study Center

Recruiting

SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast) (SEQUEL-Breast)

Neoplasm, Breast | Congenital, Familial and Genetic Disorders

Netherlands
International Cancer Research Group, United Arab...
King Saud University Medical City, Riyadh, Saudi Arabia; Max-Planck-Institut... and other collaborators

Recruiting

Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies. (ICRG0201)

Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer

Algeria, Jordan, Saudi Arabia
University Hospital, Akershus
Vestre Viken Hospital Trust; Novartis

Recruiting

Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole (NEOLETRIB)

Breast Cancer | Locally Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Luminal A Breast Cancer | Luminal B Breast Cancer

Norway
Zhejiang Cancer Hospital

Not yet recruiting

RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast Cancer

Recurrence | Breast Cancer
Peking University People's Hospital

Recruiting

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

HER2-negative Early Breast Cancer

China
Institut du Cancer de Montpellier - Val d'Aurelle

Recruiting

Diet Modification in pAtients With Luminal Early Breast Cancer Candidate for Primary Surgery (MACS)

Breast Cancer | Surgery

France
Fudan University

Recruiting

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (MULAN)

Breast Cancer | Metastatic Cancer

China
Centre Jean Perrin

Recruiting

Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer (XenoBreast)

Breast Cancer Female

France
Shengjing Hospital

Recruiting

Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer

Breast Neoplasms

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

Breast Neoplasms

China
The Netherlands Cancer Institute
Bristol-Myers Squibb

Recruiting

Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO (BELLINI)

Breast Cancer

Netherlands
Xijing Hospital

Recruiting

Immediate Breast Reconstruction With Free Greater Omentum

Breast Reconstruction

China
University Hospital, Grenoble

Recruiting

Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone (Néo-APBI-01)

Radiation Therapy, Breast Cancer, Sequential Partial Breast Irradiation | Intermediate and High-risk Luminal and Triple Negative Breast Cancer

France
Jules Bordet Institute
AstraZeneca; Institut Curie

Active, not recruiting

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (Neo-CheckRay)

Luminal B

France, Belgium
AHS Cancer Control Alberta

Active, not recruiting

A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers (PRESTO)

Estrogen Receptor Positive Breast Cancer

Canada
SOLTI Breast Cancer Research Group
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression (TATEN)

Metastatic Breast Cancer

Spain
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nipple Aspirate Fluid in Detecting Breast Cancer

Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC... and other conditions

United States
Queen Mary University of London
Merck Sharp & Dohme LLC; European Institute of Oncology

Withdrawn

Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer (PELICAN)

Breast Cancer
Grand Hôpital de Charleroi
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Completed

Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (B-IMMUNE)

Breast Cancer | Triple Negative Breast Cancer | Luminal B

Belgium
MedSIR
GlaxoSmithKline

Completed

Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) (LUZERN)

Breast Cancer | Breast Cancer Metastatic

Spain
Alpha Tau Medical LTD.

Terminated

Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases

Metastatic Breast Cancer | Breast Carcinoma | Invasive Breast Cancer | Distant Metastases.Pathology

Russian Federation
MedSIR
Cellestia Biotech AG

Terminated

CB-103 Plus NSAI In Luminal Advanced Breast Cancer (CAILA)

Advanced Breast Cancer

Spain
Institut Curie

Active, not recruiting

Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)

Triple Negative Breast Cancer | Pediatric Cancer | Metastatic Uveal Melanoma | Luminal B Breast Cancer

France
Spanish Breast Cancer Research Group

Active, not recruiting

Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer (NIKOLE)

Metastatic Breast Cancer

Spain
European Institute of Oncology
Janssen-Cilag International NV

Active, not recruiting

CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER

Breast Cancer

Italy
Borstkanker Onderzoek Groep
Novartis; Philips Healthcare

Active, not recruiting

Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. (NEOLBC)

Breast Neoplasms

Netherlands
Ontario Clinical Oncology Group (OCOG)
British Columbia Cancer Agency

Active, not recruiting

A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer (LUMINA)

Breast Cancer

Canada
Blokhin's Russian Cancer Research Center
Russian Society of Clinical Oncology

Completed

Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia. (ATLANT)

Metastatic Disease | HR+/HER2- Breast Cancer | Аdvanced Disease

Russian Federation
Spanish Breast Cancer Research Group
Celgene

Completed

Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer

Breast Cancer

Spain
International Cancer Research Group, United Arab...
Pfizer; AstraZeneca; Genomic Health®, Inc.

Completed

Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant (SAFIA)

Breast Neoplasm Female

United Arab Emirates, Algeria, Egypt, Jordan, Lebanon, Morocco, Saudi Arabia, Tunisia
Spanish Breast Cancer Research Group
AstraZeneca

Terminated

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

Breast Cancer

Spain
Hellenic Cooperative Oncology Group

Active, not recruiting

Investigation of Genomic Alteration in Patients With Luminal A or Luminal B Subtypes

Breast Cancer

Greece
Spanish Breast Cancer Research Group
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz; Faculty...

Completed

Effect of Physical Exercise on Tumor Proliferation of Luminal B Breast Cancer Patients (EFIK)

Breast Cancer | Luminal B

Spain
Istanbul Training and Research Hospital

Completed

The Relationship Between the Differences in Blood Cytokine Values in Breast Cancers.

Breast Cancer

Turkey
UNICANCER
Pfizer; NanoString Technologies, Inc.

Completed

Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women (NeoPAL)

Neoadjuvant Operable Breast Cancer

France
Thomas Hatschek

Active, not recruiting

Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases (PREDIX LumB)

Early-Stage Breast Carcinoma | Estrogen Receptor Positive Tumor

Sweden
SOLTI Breast Cancer Research Group
Novartis

Completed

Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer. (CORALLEEN)

Breast Cancer

Spain

Search clinical trials for: Luminal B breast cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations